Clinical trial NCT06522412: The Effects of Jing-Si Herbal Tea Liquid Packets and Jing-Si Herbal Tang Heng Power Drink
Official title: The Effects of Jing-Si Herbal Tea Liquid Packets and Jing-Si Herbal Tang Heng Power Drink on Metabolism and Inflammation in Patients With Cardiovascular Diseases
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Inflammatory Marker
Gut Microbiome
Trimethylamine N-oxide
HbA1c
Atherosclerosis
Keywords: trimethylamine N-oxide
gut microbiome
cardiovascular disease
atherosclerosis
Lead sponsor: Buddhist Tzu Chi General Hospital
Sponsor class: OTHER
First posted: 2024-07-26
Enrollment: 200
Sex: ALL
Minimum age (years): 20
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: Through empirical research evaluating the effects of "JING SI HERBAL TEA LIQUID PACKETS" and "JING SI HERBAL TANG HENG POWDER DRINK" as adjunctive treatments for various cardiovascular diseases, we aim to provide sufficient evidence to address the following questions:

1. Can "JING SI HERBAL TEA LIQUID PACKETS" and "JING SI HERBAL TANG HENG POWDER DRINK" significantly improve various inflammatory responses involved in the process of atherosclerosis, thereby enhancing the prognosis of patients with acute coronary syndrome and chronic ischemic heart disease?
2. Can "JING SI HERBAL TEA LIQUID PACKETS" and "JING SI HERBAL TANG HENG POWDER DRINK" provide a healthy and effective adjunctive therapy for patients with hypertension, diabetes, and hyperlipidemia by lowering blood pressure (potentially related to known ACE2 receptors), blood glucose levels (including the improvement of pancreatic β-cell insulin secretion capacity and cellular insulin utilization efficiency), and cholesterol levels?
3. Can "JING SI HERBAL TEA LIQUID PACKETS" and "JING SI HERBAL TANG HENG POWDER DRINK" influence the prognosis of various diseases, including the most critical cardiovascular conditions such as acute coronary syndrome and chronic ischemic heart disease, by altering the human gut microbiota?
4. Can "JING SI HERBAL TEA LIQUID PACKETS" and "JING SI HERBAL TANG HENG POWDER DRINK" improve renal indicators such as BUN, creatinine, UACR, and eGFR, thereby protecting the kidneys and reducing complications like microalbuminuria?

Detailed description: The Jing-Si Herbal Drink is composed of eight native Taiwanese herbal ingredients: mugwort, fishwort, houttuynia, dwarf lilyturf, balloon flower, perilla leaf, chrysanthemum, and licorice. These ingredients are known for their properties to clear heat, dispel cold, ventilate the lungs, transform phlegm, and eliminate dampness. Preliminary cell and animal studies have demonstrated that this drink can block the binding of the novel coronavirus (SARS-CoV-2) to cells and reduce cellular penetration, thereby preventing the virus from entering the cells. Recently, the Jing-Si Herbal Drink in powder form, known as "Jing-Si Herbal Drink Concentrate Powder," received an export-specific license from the Ministry of Health and Welfare. A research team from Taipei Tzu Chi Hospital has confirmed that combining standard treatment with Jing-Si Herbal Drink provides good clinical protective effects and safety for patients with mild to moderate COVID-19.

Angiotensin-converting enzyme 2 (ACE2), encoded by the ACE2 gene located on the X chromosome, regulates blood pressure and endocrine functions by clearing the vasopressor angiotensin II (Ang II), thereby allowing blood vessels to relax. Studies have shown that the human ACE2 receptor is the gateway for the novel coronavirus (SARS-CoV-2) to enter cells. Both the novel coronavirus and the SARS coronavirus must bind to the ACE2 receptor via their spike proteins to enter cells and replicate extensively, leading to pathogenicity. It is therefore reasonable to hypothesize that the Jing-Si Herbal Drink may block the binding of the novel coronavirus (SARS-CoV-2) to cells by regulating the ACE2 receptor.

Recently, the basic medical research team on herbal drinks at Hualien Tzu Chi Hospital has demonstrated through animal experiments that the Jing-Si Herbal Drink has significant anti-aging protective effects on cardiovascular and metabolic functions in aged rats (24-month-old WKY rats). Additionally, a preliminary analysis conducted by Professor Hong-Chih Han's laboratory at the Hualien Tzu Chi Hospital's Innovation and Research Center revealed that various aspects of immune function were positively affected by the Jing-Si Herbal Drink. It was observed that IFN-γ levels in the blood of subjects significantly increased 48-96 hours after consumption of the Jing-Si Herbal Drink, suggesting that it plays an important role in immune regulation.

The Jing-Si Abode Herbal Research and Development Team has built upon the original Jing-Si Herbal Drink formula to create a new generation of herbal beverage: Jing-Si Herbal Sugar-Balance Beverage. This new formula incorporates pumpkin powder and bitter melon extract powder (containing bitter melon peptides) in addition to the eight original herbal ingredients of the concentrated herbal drink. It is expected to provide enhanced protection for blood sugar and lipid metabolism as well as immune function. Recently, the basic medical research team on herbal drinks at Hualien Tzu Chi Hospital conducted animal experiments that preliminarily confirmed the superior blood sugar-lowering effects of the Jing-Si Herbal Sugar-Balance Beverage formula in diabetic rats compared to the original Jing-Si Herbal Drink formula and the drug Metformin.

The investigators will leverage the professional care provided by clinical physicians and the analytical research capabilities of our basic laboratory to collaboratively evaluate the effects of "Jing-Si Herbal Drink Concentrate" and "Jing-Si Herbal Drink Sugar-Balance Beverage" as adjunctive treatments for patients with various cardiovascular diseases. The investigators aim to not only improve the quality of life for these patients but also achieve beneficial outcomes in treating some clinically challenging diseases and symptoms.

Eligibility criteria: Inclusion Criteria:

1. Age 20-75 years.
2. Diagnosed with any of the following diseases:

(1) Hypertension (2) Hyperlipidemia (3) Diabetes (4) Ischemic heart disease"

Exclusion Criteria:

1. History of cancer.
2. Subjects with severe or poorly controlled chronic diseases as determined by the principal investigator.
3. Poor renal function (eGFR \<40 ml/min/1.73m²).
4. Pregnant or breastfeeding at the time of screening.

Primary outcomes:
measure: Effect of intervention on lipid profile
timeFrame: Baseline, 4 and 12 weeks after intervention is given.
measure: Effect of blood uric acid on Cardiovascular Disease and body inflammation status
timeFrame: Baseline, 4 and 12 weeks after intervention is given.
measure: Effect of intervention on fasting sugar
timeFrame: Baseline, 4 and 12 weeks after intervention is given.
measure: To evaluate the metabolic health
timeFrame: Baseline, 4 and 12 weeks after intervention is given.
measure: Long term blood sugar status
timeFrame: Baseline, 4 and 12 weeks after intervention is given.
measure: Homeostatic model assessment (HOMA) of insulin resistance
timeFrame: Baseline, 4 and 12 weeks after intervention is given.
measure: Inflammation biomarkers
timeFrame: Baseline, 4 and 12 weeks after each intervention is given.
measure: The hematological parameter for systemic inflammation and stress
timeFrame: Baseline, 4 and 12 weeks after each intervention is given.
measure: proinflammtory marker
timeFrame: Baseline, 4 and 12 weeks after each intervention is given.
measure: Liver function
timeFrame: Baseline, 4 and 12 weeks after each intervention is given
measure: Kidney function
timeFrame: Baseline, 4 and 12 weeks after each intervention is given
measure: Evaluation of activity of gut microbiome
timeFrame: Baseline, 4 and 12 weeks after each intervention is given
measure: The concentration of the product of gut microbiome
timeFrame: Baseline, 4 and 12 weeks after each intervention is given
measure: Analysis of Gut Microbiota in Stool Samples Using 16S rRNA Sequencing
timeFrame: Stool samples will be collected at baseline (prior to intervention) and at 12 months post-intervention to assess changes in gut microbiota composition and abundance.
measure: Body fat composition
timeFrame: Baseline, 4 and 12 weeks after each intervention is given
measure: To evaluate the distribution of body fat
timeFrame: Baseline, 4 and 12 weeks after each intervention is given
measure: Effect of intervention on blood pressure control
timeFrame: Baseline, 4 and 12 weeks after each intervention is given
measure: Measurement of overall immune function and response to infection or inflammation
timeFrame: Baseline, 4 and 12 weeks after each intervention is given
measure: Evaluate the immune system function
timeFrame: Baseline, 4 and 12 weeks after each intervention is given
measure: Assessment of leukocyte activation
timeFrame: Baseline, 4 and 12 weeks after each intervention is given
measure: To evaluates the body's ability to fight tumors and infections.
timeFrame: Baseline, 4 and 12 weeks after each intervention is given
measure: To assess immune activation and the ability to present antigens to T cells
timeFrame: Baseline, 4 and 12 weeks after each intervention is given
measure: Assessment of immune response
timeFrame: Baseline, 4 and 12 weeks after each intervention is given
measure: Marker of inflammation
timeFrame: Baseline, 4 and 12 weeks after each intervention is given
Secondary outcomes:
Other outcomes:
Locations:
city: Hualien City
country: Taiwan
facility: Hualien Tzu Chi Hospital
Study officials:
References: